Accentia Biopharmaceuticals (ABPI) Announces that FDA Grants Orphan Drug Status for Revimmune(TM) Therapy for the Prevention of Graft-Versus-Host Disease in Bone Marrow Transplant  
9/14/2011 9:20:40 AM

TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI) and its majority-owned subsidiary, Biovest International, Inc. (OTCQB:BVTI), today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune™, the Company’s proprietary system-of-care based on high-dose administration of Cytoxan® (cyclophosphamide), for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant. GVHD is a life-threatening autoimmune complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted cells trigger an immune attack on the transplant recipient's body.